Advertisement
Screener

CYTOKINETICS, INCORPORATED (CYTK) Interest Expense

2.8 / 5 stars · 68/120 Roast Me

CYTOKINETICS, INCORPORATED Interest Expense

CYTOKINETICS, INCORPORATED (CYTK) reported Interest Expense of $45.58 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.

Financial Statements › Expense Statement › Interest Expense

us-gaap:InterestExpense · last filed 2026-02-26

  • CYTOKINETICS, INCORPORATED interest expense for the quarter ending 2025-12-31 was $14.27M, a 59.70% increase year-over-year.
  • CYTOKINETICS, INCORPORATED interest expense for the quarter ending 2025-09-30 was $11.35M, a 27.16% increase year-over-year.
  • CYTOKINETICS, INCORPORATED interest expense for the quarter ending 2025-06-30 was $11.08M, a 12.94% decline year-over-year.
  • CYTOKINETICS, INCORPORATED interest expense for the quarter ending 2025-03-31 was $8.87M, a 24.85% increase year-over-year.
  • CYTOKINETICS, INCORPORATED interest expense for fiscal 2025 was $45.58M, a 20.90% increase from fiscal 2024.
  • CYTOKINETICS, INCORPORATED interest expense for fiscal 2024 was $37.70M, a 33.19% increase from fiscal 2023.
  • CYTOKINETICS, INCORPORATED interest expense for fiscal 2023 was $28.31M, a 45.80% increase from fiscal 2022.
  • CYTOKINETICS, INCORPORATED interest expense for fiscal 2022 was $19.41M, a 18.09% increase from fiscal 2021.
Period endInterest Expense 3 monthInterest Expense 3 month as first filedInterest Expense 6 monthInterest Expense 9 monthInterest Expense 12 monthInterest Expense 185 month
2025-12-31$14.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$25.63M
derived: sum of 2 quarters · filed 2026-02-26
$36.71M
derived: sum of 3 quarters · filed 2026-02-26
$45.58M
10-K · filed 2026-02-26
2025-09-30$11.35M
10-Q · filed 2025-11-05
$22.44M
derived: sum of 2 quarters · filed 2025-11-05
$31.30M
10-Q · filed 2025-11-05
$40.24M
derived: sum of 4 quarters · filed 2026-02-26
2025-06-30$11.08M
10-Q · filed 2025-08-07
$19.95M
10-Q · filed 2025-08-07
$28.89M
derived: sum of 3 quarters · filed 2026-02-26
$37.82M
derived: sum of 4 quarters · filed 2026-02-26
2025-03-31$8.87M
derived: 10-K 12 month − 3 quarters · filed 2026-02-26
$17.81M
derived: sum of 2 quarters · filed 2026-02-26
$26.73M
derived: sum of 3 quarters · filed 2026-02-26
$39.47M
derived: sum of 4 quarters · filed 2026-02-26
2024-12-31$8.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$17.87M
derived: sum of 2 quarters · filed 2026-02-26
$30.60M
derived: sum of 3 quarters · filed 2026-02-26
$37.70M
10-K · filed 2026-02-26
2024-09-30$8.93M
10-Q · filed 2025-11-05
$21.66M
derived: sum of 2 quarters · filed 2025-11-05
$28.76M
10-Q · filed 2025-11-05
$35.93M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30$12.73M
10-Q · filed 2025-08-07
$19.84M
10-Q · filed 2025-08-07
$27.00M
derived: sum of 3 quarters · filed 2026-02-26
$34.13M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31$7.10M
10-Q · filed 2024-05-10
$14.27M
derived: sum of 2 quarters · filed 2026-02-26
$21.40M
derived: sum of 3 quarters · filed 2026-02-26
$28.45M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$7.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$14.30M
derived: sum of 2 quarters · filed 2026-02-26
$21.34M
derived: sum of 3 quarters · filed 2026-02-26
$28.31M
10-K · filed 2026-02-26
2023-09-30$7.14M
10-Q · filed 2024-11-07
$14.18M
derived: sum of 2 quarters · filed 2024-11-07
$21.14M
10-Q · filed 2024-11-07
$28.20M
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30$7.04M
10-Q · filed 2024-08-09
$14.01M
10-Q · filed 2024-08-09
$21.06M
derived: sum of 3 quarters · filed 2025-02-27
$27.87M
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31$6.96M
10-Q · filed 2024-05-10
$14.02M
derived: sum of 2 quarters · filed 2025-02-27
$20.82M
derived: sum of 3 quarters · filed 2025-02-27
$23.63M
derived: sum of 4 quarters · filed 2025-02-27
2022-12-31$7.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
$13.86M
derived: sum of 2 quarters · filed 2025-02-27
$16.67M
derived: sum of 3 quarters · filed 2025-02-27
$19.41M
10-K · filed 2025-02-27
2022-09-30$6.80M
10-Q · filed 2023-11-03
$9.61M
derived: sum of 2 quarters · filed 2023-11-03
$12.36M
10-Q · filed 2023-11-03
$16.57M
derived: sum of 4 quarters · filed 2024-02-28
2022-06-30$2.81M
10-Q · filed 2023-08-03
$5.55M
10-Q · filed 2023-08-03
$9.77M
derived: sum of 3 quarters · filed 2024-02-28
$13.93M
derived: sum of 4 quarters · filed 2024-02-28
2022-03-31$2.75M
10-Q · filed 2023-05-05
$6.96M
derived: sum of 2 quarters · filed 2024-02-28
$11.13M
derived: sum of 3 quarters · filed 2024-02-28
$15.20M
derived: sum of 4 quarters · filed 2024-02-28
2021-12-31$4.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28
$8.38M
derived: sum of 2 quarters · filed 2024-02-28
$12.45M
derived: sum of 3 quarters · filed 2024-02-28
$16.44M
10-K · filed 2024-02-28
2021-09-30$4.16M
10-Q · filed 2022-11-04
$8.23M
derived: sum of 2 quarters · filed 2022-11-04
$12.22M
10-Q · filed 2022-11-04
$16.24M
derived: sum of 4 quarters · filed 2023-03-01
2021-06-30$4.07M
10-Q · filed 2022-08-05
$8.06M
10-Q · filed 2022-08-05
$12.08M
derived: sum of 3 quarters · filed 2023-03-01
$16.05M
derived: sum of 4 quarters · filed 2023-03-01
2021-03-31$3.99M
10-Q · filed 2022-05-06
$8.01M
derived: sum of 2 quarters · filed 2023-03-01
$11.98M
derived: sum of 3 quarters · filed 2023-03-01
$15.87M
derived: sum of 4 quarters · filed 2023-03-01
2020-12-31$4.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$7.99M
derived: sum of 2 quarters · filed 2023-03-01
$11.89M
derived: sum of 3 quarters · filed 2023-03-01
$15.96M
10-K · filed 2023-03-01
2020-09-30$3.98M
10-Q · filed 2021-11-05
$7.87M
derived: sum of 2 quarters · filed 2021-11-05
$11.95M
10-Q · filed 2021-11-05
$14.68M
derived: sum of 4 quarters · filed 2022-02-25
2020-06-30$3.89M
10-Q · filed 2021-08-06
$7.97M
10-Q · filed 2021-08-06
$10.70M
derived: sum of 3 quarters · filed 2022-02-25
$12.04M
derived: sum of 4 quarters · filed 2022-02-25
2020-03-31$4.08M
10-Q · filed 2021-05-07
$6.81M
derived: sum of 2 quarters · filed 2022-02-25
$8.15M
derived: sum of 3 quarters · filed 2022-02-25
$9.53M
derived: sum of 4 quarters · filed 2022-02-25
2019-12-31$2.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25
$4.08M
derived: sum of 2 quarters · filed 2022-02-25
$5.45M
derived: sum of 3 quarters · filed 2022-02-25
$6.62M
10-K · filed 2022-02-25
2019-09-30$1.34M
10-Q · filed 2020-11-06
$2.72M
derived: sum of 2 quarters · filed 2020-11-06
$3.89M
10-Q · filed 2020-11-06
$5.06M
derived: sum of 4 quarters · filed 2021-02-26
2019-06-30$1.38M
10-Q · filed 2020-08-07
$2.55M
10-Q · filed 2020-08-07
$3.72M
derived: sum of 3 quarters · filed 2021-02-26
$4.58M
derived: sum of 4 quarters · filed 2021-02-26
2019-03-31$1.17M
10-Q · filed 2020-05-08
$2.34M
derived: sum of 2 quarters · filed 2021-02-26
$3.21M
derived: sum of 3 quarters · filed 2021-02-26
$4.10M
derived: sum of 4 quarters · filed 2021-02-26
2018-12-31$1.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26
$2.04M
derived: sum of 2 quarters · filed 2021-02-26
$2.93M
derived: sum of 3 quarters · filed 2021-02-26
$3.80M
10-K · filed 2021-02-26
2018-09-30$867.00K
10-Q · filed 2019-11-01
$1.76M
derived: sum of 2 quarters · filed 2019-11-01
$2.63M
10-Q · filed 2019-11-01
$3.30M
derived: sum of 4 quarters · filed 2019-11-01
2018-06-30$898.00K
10-Q · filed 2019-08-09
$1.76M
10-Q · filed 2019-08-09
$2.43M
derived: sum of 3 quarters · filed 2019-08-09
$3.24M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31$863.00K
10-Q · filed 2019-05-09
$1.53M
derived: sum of 2 quarters · filed 2019-05-09
$2.34M
derived: sum of 3 quarters · filed 2019-05-09
$3.12M
derived: sum of 4 quarters · filed 2019-05-09
2017-12-31$670.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07
$1.48M
derived: sum of 2 quarters · filed 2019-03-07
$2.26M
derived: sum of 3 quarters · filed 2019-03-07
$3.02M
10-K · filed 2019-03-07
2017-09-30$806.00K
10-Q · filed 2018-11-09
$1.59M
derived: sum of 2 quarters · filed 2018-11-09
$2.35M
10-Q · filed 2018-11-09
$3.05M
derived: sum of 4 quarters · filed 2018-11-09
2017-06-30$782.00K
10-Q · filed 2018-08-07
$1.54M
10-Q · filed 2018-08-07
$2.24M
derived: sum of 3 quarters · filed 2018-08-07
$2.95M
derived: sum of 4 quarters · filed 2018-08-07
2017-03-31$745.00K
10-Q · filed 2018-05-10
$3.05M
10-Q · filed 2017-05-04
$1.46M
derived: sum of 2 quarters · filed 2018-05-10
$2.17M
derived: sum of 3 quarters · filed 2018-05-10
$2.88M
derived: sum of 4 quarters · filed 2018-05-10
2016-12-31$713.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05
$1.43M
derived: sum of 2 quarters · filed 2018-03-05
$2.13M
derived: sum of 3 quarters · filed 2018-03-05
$2.70M
10-K · filed 2018-03-05
2016-09-30$714.00K
10-Q · filed 2017-11-03
$1.42M
derived: sum of 2 quarters · filed 2017-11-03
$1.99M
10-Q · filed 2017-11-03
$2.25M
derived: sum of 4 quarters · filed 2018-03-05
2016-06-30$707.00K
10-Q · filed 2017-08-04
$1.27M
10-Q · filed 2017-08-04
$1.54M
derived: sum of 3 quarters · filed 2018-03-05
$1.54M
derived: sum of 4 quarters · filed 2018-03-05
2016-03-31$563.00K
10-Q · filed 2017-05-04
$831.00K
derived: sum of 2 quarters · filed 2018-03-05
$831.00K
derived: sum of 3 quarters · filed 2018-03-05
2015-12-31$268.00K
derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-05
$268.00K
derived: sum of 2 quarters · filed 2018-03-05
$268.00K
10-K · filed 2018-03-05
2015-09-30$0.00
10-Q/A · filed 2016-12-15
$0.00
10-Q/A · filed 2016-12-15
2014-12-31$0.00
10-K · filed 2017-03-06
2013-12-31$0.00
10-K · filed 2015-03-06
2012-12-31$3.00K
10-K · filed 2015-03-06
$5.38M
10-K · filed 2013-03-15
2011-12-31$35.00K
10-K · filed 2014-03-07
2010-12-31$176.00K
10-K · filed 2013-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
Alkermes plc. (ALKS)$6.844B132.74